Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 23;7(4):e67-e68.
doi: 10.1093/ehjcvp/pvab039.

SGLT2 inhibitors in cardiovascular medicine

Fahimeh Varzideh  1   2 , Urna Kansakar  1   2 , Gaetano Santulli  1   2
Affiliations

SGLT2 inhibitors in cardiovascular medicine

Fahimeh Varzideh et al. Eur Heart J Cardiovasc Pharmacother. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cartoon depicting the mechanism of action of SGLT2 inhibitors and their beneficial effects of on the cardiovascular system. AGE-RAGE, advanced glycation end products/receptor; ECC, excitation–contraction coupling; PCT, proximal convoluted tubule.
See this image and copyright information in PMC

References

    1. Kalyani RR.Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes. NEJM 2021;384:1248–1260. - PubMed
    1. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J, Squire I, Taddei S, Wanner C, Zannad F.. Cardiovascular and renal outcomes with empagliflozin in heart failure. NEJM 2020;383:1413–1424. - PubMed
    1. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM 2017;377:644–657. - PubMed
    1. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M.. Dapagliflozin in patients with heart failure and reduced ejection fraction. NEJM 2019;381:1995–2008. - PubMed
    1. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B.. Sotagliflozin in patients with diabetes and recent worsening heart failure. NEJM 2021;384:117–128. - PubMed

MeSH terms

Substances